The transdermal delivery system of monoamine oxidase inhibitors

Journal of Clinical Psychiatry

Volumn 73, Issue SUPPL. 1, 2012, Pages 25-30

  VanDenBerg, Chad M ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SELEGILINE;

APPLICATION SITE REACTION; CARDIOVASCULAR DISEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSIVE CRISIS; INSOMNIA; IRRITANT DERMATITIS; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; MYALGIA; MYOCLONUS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; TRANSDERMAL PATCH; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WEIGHT GAIN;

EID: 84864842044     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11096su1c.04     Document Type: Review

References (29)

1. Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141(1):89-101. doi:10.1016/j.psychres.205.07.012 PubMed
2. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression - a retrospective study. J Affect Disord. 2005;89(1-3):183-188. doi:10.1016/j.jad.205.06.01 PubMed
3. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65(suppl 4):5-10. PubMed
4. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(suppl 8):35-41. PubMed
5. Baker GB, Coutts RT, McKenna KF, et al. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci. 1992;17(5):206-214. PubMed
6. Schatzberg AF, Nemeroff CB. The American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998.
7. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855-870. PubMed
8. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46(1):45-50. doi:10.101/archpsyc. 1989.01810104707 PubMed
9. Schulz R, Antonin KH, Hoffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther. 1989;46(5):528-536. doi:10.1038/clpt.1989.181 PubMed
10. Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994;56(6 pt 2):742-749. doi:10.1038/clpt.194.204 PubMed
11. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004;10(4):239-248. doi:10.1097/0131746-204070-05 PubMed
12. Culpepper L, Kovalick LJ. A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. doi:10.408/PC.v10n0105 PubMed
13. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57(3):99-104. PubMed
14. Stahl MS. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press; 2008.
15. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226-247. doi:10.1016/S0893-13X(98)075-X PubMed
16. Azzaro AJ, Ziemniak J, Kemper E, et al. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007;47(10):1256-1267. doi:10.17/091270730479 PubMed
17. EMSAM (selegiline patch) [package insert]. Napa, CA: Dey Pharma LP; 2010. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b891bd9f-fdb8-4862-89c5- ecdd700398a3. Accessed April 20, 2012.
18. Pae CU, Lim HK, Han C, et al. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1153-1163. doi:10.1016/j.pnpbp.207.04.020 PubMed
19. Azzaro AJ, Vandenberg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects [published correction appears in J Clin Psychopharmacol. 2006;46(10):1225-1226]. J Clin Pharmacol. 2006;46(8):933-944. doi:10.17/0912706289852 PubMed
20. Wagner GC, Walsh SL. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage. Int J Dev Neurosci. 1991;9(2):171-174. doi:10.1016/0736-5748(91)908-A PubMed
21. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55(1):27-34. doi:10.1/j.2042-7158.203.tb02430.x PubMed
22. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208-214. doi:10.408/JCP.v64n0216 PubMed
23. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869-1875. doi:10.176/api.ajp.159.1.1869 PubMed
24. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, doubleblind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579-586. doi:10.1097/01.jcp.0239794.37073.70 PubMed
25. Pauporte M, Goodhead M, Azzaro AJ, et al. Selegiline transdermal system (STS): preclinical assays of dermal safety. Cutan Ocul Toxicol. 2005;23(3):173-178. doi:10.1081/CUS-2035363
26. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26(10):920-935. doi:10.107/s12325-09-075-9 PubMed
27. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354-1361. doi:10.408/JCP.v67n0905 PubMed
28. Farlow MR, Somogyi M. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. Prim Care Companion CNS Disord. 2011;13(6):doi:10.4088/PCC.11r01149. doi:10.408/PC.1r0149
29. Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology. 2007;69(suppl 1):S4-S9. doi:10.1212/01.wnl.0281845.40390.8b PubMed